Which way will CDTX go? Request
Key Stats
Beta 0.54
* uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] The Cidara Therapeutics stock currently holds an RSI14 at 20 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

Stronger technical forecast for Cidara Therapeutics stock price after Friday trading. (Updated on July 30, 2021)

Sell candidate since 2021-07-01 Loss -23.62%

The Cidara Therapeutics stock price gained 2.70% on the last trading day (Friday, 30th Jul 2021), rising from $1.48 to $1.52. During the day the stock fluctuated 4.67% from a day low at $1.50 to a day high of $1.57. The price has fallen in 6 of the last 10 days and is down by -4.4% for this period. Volume fell on the last day by -28 thousand shares and in total, 335 thousand shares were bought and sold for approximately $508.65 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $1.47 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -21.22% during the next 3 months and, with a 90% probability hold a price between $1.16 and $1.50 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Thursday, July 29, 2021, and so far it has risen 2.70%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Cidara Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.52 and $1.83. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD). Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.

Support, Risk & Stop-loss

Cidara Therapeutics finds support from accumulated volume at $1.50 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0700 between high and low, or 4.67%. For the last week the stock has had a daily average volatility of 4.41%.

Cidara Therapeutics is oversold on RSI14 (20). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Cidara Therapeutics stock A Buy?

Cidara Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.

Current score: -2.192

Predicted Opening Price for Cidara Therapeutics of Monday, August 2, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price August 2, 2021 Current price
$1.53 $1.52 (Undervalued)
Sell Candidate Upgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

Aegis is very positive about CDTX and gave it a "Buy" rating on March 10, 2021. The price target was set to $9.00.

4.41 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $1.70
Price: $1.52
Support: $1.50

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 1.60 5.26 %
1.57 3.50 %
1.56 2.42 %
Current price: 1.52
Support 1.50 -1.10 %
1.49 -2.19 %
1.46 -3.95 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 1.87 23.03 %
1.83 20.39 %
1.70 11.84 %
Current price 1.52
Support 1.50 -1.32%
1.48 -2.63%
0 .

Click to get the best stock tips daily for free!

About Cidara Therapeutics

Cidara Therapeutics Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vul... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE